Short answer
ARVINAS, INC. (ARVN) filed an 8-K current report with the SEC on March 18, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Positive Phase 1 data for ARV-102 showing >50% LRRK2 degradation in cerebrospinal fluid after 28 days in Parkinson’s patients.
ARVINAS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive Phase 1 data for ARV-102 showing >50% LRRK2 degradation in cerebrospinal fluid after 28 days in Parkinson’s patients
- ARV-102 is an oral PROTAC designed to cross the blood-brain barrier targeting LRRK2, a key Parkinson's disease protein
- Data from randomized, double-blind, placebo-controlled multiple dose cohort presented at AD/PD™ 2026 conference
- Clinical progress validates Arvinas’ brain-penetrant PROTAC platform, enhancing pipeline and future therapeutic potential
- Data release may boost investor confidence and valuation based on first clinical proof of mechanism in neurodegeneration
Item 8.01 · Other Events
- Positive Phase 1 data for ARV-102 showing >50% LRRK2 degradation in CSF of Parkinson’s patients after 28 days treatment
- ARV-102 well tolerated at 20 mg, 40 mg, 80 mg doses, no serious adverse events or lung function issues observed
- Drug demonstrated dose-dependent brain penetration with plasma half-life of 68 hours, supporting once-daily oral dosing
- Biomarker reductions (CD68, GPNMB) indicate target engagement relevant to LRRK2-related neuroinflammation and disease pathology
- Plans to start Phase 1b trial in progressive supranuclear palsy Q2 2026 and potential registrational trial in late 2026 signal accelerated development path
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARVINAS, INC. 8-K filings
Get the next ARVN 8-K as it lands
Follow ARVN for push alerts, or ask the research agent what this filing means.